A randomized , open-label, parallel group study to evaluate the efficacy and safety of Alirocumab versus usual care in patients with type 2 diabetes and mixed dyslipidemia at high cardiovascular risk with Non-HDL-C not adequately controlled with maximally tolerated statin therapy